[go: up one dir, main page]

DE3744785A1 - Use of retrograde mirror-image antisense nucleic acids against cancers - Google Patents

Use of retrograde mirror-image antisense nucleic acids against cancers

Info

Publication number
DE3744785A1
DE3744785A1 DE19873744785 DE3744785A DE3744785A1 DE 3744785 A1 DE3744785 A1 DE 3744785A1 DE 19873744785 DE19873744785 DE 19873744785 DE 3744785 A DE3744785 A DE 3744785A DE 3744785 A1 DE3744785 A1 DE 3744785A1
Authority
DE
Germany
Prior art keywords
nucleic acids
oncogenes
mirror
retrograde
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19873744785
Other languages
German (de)
Inventor
Karl E Prof Dr Med Theurer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THEURER KARL EUGEN
Original Assignee
THEURER KARL EUGEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THEURER KARL EUGEN filed Critical THEURER KARL EUGEN
Priority to DE19873742049 priority Critical patent/DE3742049A1/en
Priority to DE19873744785 priority patent/DE3744785A1/en
Publication of DE3744785A1 publication Critical patent/DE3744785A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Divided out of P 3742049.6-41, retrograde mirror-image antisense nucleic acids (RNA or DNA) of proto-oncogenes or oncogenes or parts of these are used as vaccines for the diagnosis, prophylaxis and therapy of appropriate cancers.

Description

Vorliegendes Anwendungsverfahren ist ein ausgeschiedener Teil von P 37 42 049.6-41, bei welchem rückläufige spiegelbildliche Anti- Sense-Nucleinsäuren, die den jeweiligen ursprünglichen DNS oder RNS des Virusgenoms oder Anteilen von diesem, die für die Virusvermehrung oder Pathogenität verantwortlich sind, entsprechen, als Impfstoffe gegen Viruserkrankungen zu diagnostischen und therapeutischen Zwecken ver­ wendet werden. Demgegenüber werden hier Anti-Sense-Nucleinsäuren bezüglich der Proto-Onkogene bzw. Onkogene oder Anteilen von diesen, die für die Krebsentstehung verantwortlich sind, verwendet. Die Gewinnung von Anti-Sense-Nucleinsäuren aufgrund der Struktur nativer Nucleinsäuren ist Stand der Wissenschaft. Die Nucleotidsequenz verschiedener Proto- Onkogene bzw. Onkogene ist bekannt. Danach kann eine rückläufige spiegelbildliche DNS oder ein Abschnitt aus dieser wie auch entsprechende Anti-Sense-mRNS synthetisiert werden.This application method is an excluded part of P 37 42 049.6-41, in which declining mirror-image anti- Sense nucleic acids that correspond to the respective original DNA or RNA of the virus genome or parts of it, which are responsible for the virus multiplication or pathogenicity are responsible, as vaccines against Viral diseases for diagnostic and therapeutic purposes ver be applied. In contrast, here are anti-sense nucleic acids with regard to the proto-oncogenes or oncogenes or parts thereof, that are responsible for the development of cancer. The extraction of anti-sense nucleic acids due to the structure of native nucleic acids is state of the art. The nucleotide sequence of various proto- Oncogenes or oncogenes are known. After that, a declining mirrored DNS or a section of this as well as corresponding Anti-sense mRNAs are synthesized.

Zur diagnostischen Anwendung sollten die Moleküle mit einem Tracer- Molekül, z. B. Radionuclide oder chemische Reagenzien bzw. Enzyme kon­ jugiert werden. Diese können dann zum Nachweis der nativen Nuclein­ säuren in Onkogenen verwendet werden.For diagnostic use, the molecules should be Molecule, e.g. B. radionuclides or chemical reagents or enzymes kon be jugged. These can then be used to detect the native nuclein acids can be used in oncogenes.

Für die therapeutische und prophylaktische Anwendung kann es nützlich sein, die Anti-Sense-Nucleinsäuren chemisch zu modifizieren um ihre intrazelluläre Vermehrung zu beeinflussen, ebenso auch zur Verbesserung der Permeabilität in Zellen. Die Inkorporierung in Liposome ist möglich. It can be useful for therapeutic and prophylactic use be to chemically modify the anti-sense nucleic acids to their To influence intracellular multiplication, also for improvement permeability in cells. Incorporation into liposomes is possible.  

Beispielexample

Es sollen Impfstoffe gegen Krebserkrankungen gewonnen werden. Dazu werden Proto-Onkogene bzw. Onkogene aus Krebszellen isoliert und ihre Nucleotidsequenz analysiert. Für verschiedene Onkogene ist diese bereits bekannt. Es werden nun nach bekannten Methoden der Polynucleotidsynthese Anti-Sense-Nucleinsäuren mit rückläufiger spiegelbildlicher Nucleotid-Sequenz, ähnlich dem Antikoton von Transfer-RNA künstlich synthetisiert und ggfs. mit einem Start- oder Stop-Signal versehen. In dieser Weise können auch aus pathogenen Abschnitten von nativen Proto-Onkogenen bzw. Onkogenen Anti-Sense-Nucleinsäuren gewonnen werden. Die gewonnenen Moleküle werden diagnostisch zum Nachweis von Prä-Onkogenen und Onkogenen verwendet, ebenso aber auch zur Prophylaxe und auch therapeutisch zur Blockierung und Inaktivierung solcher Krebs-erzeugender Faktoren.Vaccines against cancer should be obtained. To proto-oncogenes or oncogenes are isolated from cancer cells and their Nucleotide sequence analyzed. This is already for different oncogenes known. There are now known methods of polynucleotide synthesis Anti-sense nucleic acids with a retrograde mirror image nucleotide sequence, Similar to the anticoton of transfer RNA artificially synthesized and, if necessary. provided with a start or stop signal. In this way, too from pathogenic sections of native proto-oncogenes or oncogenes Anti-sense nucleic acids can be obtained. The molecules obtained become diagnostic for the detection of pre-oncogenes and oncogenes used, but also for prophylaxis and therapeutic to block and inactivate such cancer-causing factors.

Claims (1)

Verwendung von rückläufigen spiegelbildlichen Anti-Sense-Nucleinsäuren, die den jeweiligen ursprünglichen DNS oder RNS von isolierten Proto- Onkogenen bzw. Onkogenen oder Anteilen von diesen, die für das Krebs­ wachstum verantwortlich sind, entsprechen, als ausgeschiedener Teil von P 37 42 049.6-41, in Impfstoffen gegen Krebserkrankungen zu diag­ nostischen, prophylaktischen und therapeutischen Zwecken.Use of retrograde mirror-image anti-sense nucleic acids, which match the respective original DNA or RNA of isolated proto- Oncogenes or oncogenes or proportions of these that are relevant to cancer growth are responsible, as excreted part of P 37 42 049.6-41, to be diagnosed in vaccines against cancer nostic, prophylactic and therapeutic purposes.
DE19873744785 1987-12-11 1987-12-11 Use of retrograde mirror-image antisense nucleic acids against cancers Withdrawn DE3744785A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19873742049 DE3742049A1 (en) 1987-12-11 1987-12-11 Preparation and use of vaccines and diagnostic aids for viral diseases and cancers
DE19873744785 DE3744785A1 (en) 1987-12-11 1987-12-11 Use of retrograde mirror-image antisense nucleic acids against cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873742049 DE3742049A1 (en) 1987-12-11 1987-12-11 Preparation and use of vaccines and diagnostic aids for viral diseases and cancers
DE19873744785 DE3744785A1 (en) 1987-12-11 1987-12-11 Use of retrograde mirror-image antisense nucleic acids against cancers

Publications (1)

Publication Number Publication Date
DE3744785A1 true DE3744785A1 (en) 1989-08-17

Family

ID=25862686

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19873744785 Withdrawn DE3744785A1 (en) 1987-12-11 1987-12-11 Use of retrograde mirror-image antisense nucleic acids against cancers
DE19873742049 Withdrawn DE3742049A1 (en) 1987-12-11 1987-12-11 Preparation and use of vaccines and diagnostic aids for viral diseases and cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE19873742049 Withdrawn DE3742049A1 (en) 1987-12-11 1987-12-11 Preparation and use of vaccines and diagnostic aids for viral diseases and cancers

Country Status (1)

Country Link
DE (2) DE3744785A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1991003260A1 (en) * 1989-09-01 1991-03-21 Temple University Of The Commonwealth System Of Higher Education Antisense oligonucleotides to c-abl proto-oncogene
AU652006B2 (en) * 1990-10-09 1994-08-11 Nexstar Pharmaceuticals, Inc. Inhibition of viral replication
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences

Also Published As

Publication number Publication date
DE3742049A1 (en) 1989-06-22

Similar Documents

Publication Publication Date Title
Kravitz et al. Gamma-aminobutyric acid and other blocking compounds in crustacea: III. Their relative concentrations in separated motor and inhibitory axons
Doran et al. Anatomical, cellular and molecular analysis of 8,000-yr-old human brain tissue from the Windover archaeological site
NO972006D0 (en) New method for diagnosis of diseases
DE69617773T2 (en) Method for measuring oligonucleotide degradation
Mabry et al. Sialic acid in human cancer
DE69633386T2 (en) NUCLEIC ACID EQUIPMENT FOR TISSUE OBJECTIVES
FRIEDE Enzyme histochemical studies in multiple sclerosis
DE60223432T2 (en) A method of determining cell cycle regulatory factor activity and methods of diagnosing cancer using the same
DE2718542A1 (en) METHODS FOR CLEANING UP INTERFERON
CH675593A5 (en)
DE3744785A1 (en) Use of retrograde mirror-image antisense nucleic acids against cancers
Storey Somatic reduction in cycads
WO1994003196A1 (en) New tumor diagnosing or therapeutical probe
DE2840760A1 (en) METHOD AND REAGENT FOR DETECTION OF CARCINOGENIC AND ANTICANCEROGENIC SUBSTANCES
DE19916417A1 (en) New amyloid-specific aptamer, useful for diagnosis and/or treatment of e.g. Alzheimer's disease, is stabilized against nucleases
US5039619A (en) Method for detecting characteristic markers of disease in biological fluids
EP0698122B1 (en) Complex diagnostic agent of genetic expression and medical diagnosis and gene isolation process using said diagnostic agent
DE10024174A1 (en) Method for selecting inhibitors for enzymes
Giménez-Martín et al. Partial initiation of endomitosis by 3′-deoxyadenosine
DE68916905T2 (en) Specific nucleic acid fragments of human villaging, their use for diagnostic purposes.
RU2244751C2 (en) Method for identifying pharmaceutical agents from vegetable extracts
King The nucleoli and related structures in the desmids
Osztovics et al. Banding techniques in the evaluation of human chromosomal variants
DE69830169T2 (en) PROOF AND TREATMENT OF CANCER
DE3511199A1 (en) METHOD FOR THE IMMUNOLOGICAL DETERMINATION OF HEPARANESULFATE PROTEOGLYCANE, METHOD FOR THE PRODUCTION OR CLEANING OF SUITABLE HEPARANESULFATE PROTEOGLYCAN FROM TISSUE CONTAINING BASAL MEMBRANE

Legal Events

Date Code Title Description
AC Divided out of

Ref country code: DE

Ref document number: 3742049

Format of ref document f/p: P

AC Divided out of

Ref country code: DE

Ref document number: 3742049

Format of ref document f/p: P

OP8 Request for examination as to paragraph 44 patent law
8130 Withdrawal